Skip to Main Content
Imvax
  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
    • Scientific Advisors
  • Our Science
    • Overview
    • Our GoldspireTM Platform
    • Advantages
    • Publications
  • Pipeline
    • Overview
    • Imvax Programs
      • IGV-001
      • IHC-001
      • IUC-001
      • ICC-001
      • IEC-001
      • IOC-001
    • Clinical Trials
  • News & Events
  • Culture & Careers
    • Our People
    • Benefits
    • Career Opportunities

Uhl, C., et al.

Uhl, C., et al. “Autologous tumor cell immunotherapeutic platform, with evidence of clinical activity in glioblastoma, induces in vitro immune responses in both glioblastoma and endometrial cancer” Presented at CICON 2022.

601 Walnut Street, Suite 440W, Philadelphia, PA 19106
267-900-4110
contact@imvax.com

  • Careers at Imvax
  • Privacy Policy
  • Terms of Use
  • LinkedIn
  • Twitter
© Copyright 2023 Imvax®, Inc. All rights reserved.